Uncertainty in the era of precision medicine

New England Journal of Medicine

Volumn 375, Issue 8, 2016, Pages 711-713

  Hunter, David J ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GENETICS; CANCER PROGNOSIS; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; IMMUNOHISTOCHEMISTRY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROBABILITY; PROTEIN BLOOD LEVEL; SHORT SURVEY; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; ONCOLOGY; UNCERTAINTY;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MEDICAL ONCOLOGY; PRECISION MEDICINE; UNCERTAINTY;

EID: 84984674740     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1608282     Document Type: Short Survey

References (5)

1. Committee on a Framework for Developing a New Taxonomy of Disease. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. Washington, DC: National Academies Press, 2011.
2. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015;372:793-5.
3. van de Vijver MJ, He YD, van 't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
4. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
5. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-34.